Back to top

gene-editing: Archive

Zacks Equity Research

Iovance (IOVA) Announces Wider-Than-Anticipated Q4 Loss

Iovance Biotherapeutics' (IOVA) fourth-quarter loss is wider than expected. The company is on track to file regulatory submission for lifileucel in melanoma by first-half 2022.

BMYPositive Net Change MRKPositive Net Change CLLSNegative Net Change IOVAPositive Net Change

Zacks Equity Research

Intellia (NTLA) Q4 Loss Wider Than Expected, Revenues Up Y/Y

Intellia Therapeutics (NTLA) reports wider-than-expected Q4 loss. Nonetheless, revenues beat estimates.

REGNPositive Net Change VRTXPositive Net Change ABUSPositive Net Change NTLANegative Net Change

Zacks Equity Research

What to Expect From Precision BioSciences (DTIL) Q4 Earnings

On Precision BioSciences' (DTIL) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's pipeline.

MRNANegative Net Change BDSIPositive Net Change GMDAPositive Net Change DTILPositive Net Change

Zacks Equity Research

Intellia (NTLA) Up on Deal With ONK for Cancer Therapies

Intellia (NTLA) partners with ONK Therapeutics. The collaboration utilises their respective proprietary platforms to develop allogeneic CRISPR-based NK cell therapies for the treatment of cancer.

REGNPositive Net Change VRTXPositive Net Change TBPHPositive Net Change NTLANegative Net Change

Zacks Equity Research

CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards?

On CRISPR Therapeutics' (CRSP) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's pipeline candidates, especially its lead candidate CTX001.

VRTXPositive Net Change CRSPNegative Net Change VIRPositive Net Change